CEO Kevin Sharer

Biotech drugmaker Amgen Inc. introduced new CEO Bob Bradway to shareholders Wednesday at the company's annual meeting, with retiring CEO Kevin Sharer stepping down after a decade running the world's largest biotech company. At the meeting, Amgen ...  

The director nominees David Baltimore, Robert Bradway, Frank Biondi, Jr., Vance Coffman, Francois de Carbonnel, Rebecca Henderson, Frank Herringer, Gilbert S. Omenn, Judith Pelham, Paul Reason, USN (Retired), Leonard Schaeffer, Kevin Sharer and ...  

WESTLAKE VILLAGE, Calif. (AP) — Biotech drugmaker Amgen Inc. has introduced new CEO Bob Bradway to shareholders at the company's annual meeting, with retiring CEO Kevin Sharer stepping down after a decade. Stockholders of the Thousand Oaks, Calif., company voted against all four shareholder proposals. Those included bids to separate the board chairman and CEO positions, which was supported by 42 percent of shares voted, and to...  

WESTLAKE VILLAGE, Calif. — Biotech drugmaker Amgen Inc. has introduced new CEO Bob Bradway to shareholders at the company’s annual meeting, with retiring CEO Kevin Sharer stepping down after a decade. Stockholders of the Thousand Oaks, Calif.  

Kevin Sharer stepped down as CEO of Amgen Inc. on Wednesday after more than a decade piloting the Thousand Oaks biotechnology giant, allowing Bob Bradway to take over as the company's fourth CEO. "Bob is an exceptional person who's fully ready," Sharer said at Amgen's annual meeting of stockholders in Westlake Village....  

In 2011, Amgen's compensation programs were modified to reflect the core concerns of our stockholders and to better align executive pay with Amgen's performance. Today, Say-on-Pay received approximately 87 percent of the votes cast "For" the proposal.  

Amgen power handoff comes at critical timePacific Coast Business TimesIncoming Amgen chief Robert Bradway takes the baton from longtime CEO Kevin Sharer as the world's largest biotech company makes critical decisions about how it will compete with Big Pharma and biosimilars. Amgen, the Tri-Counties' only blue-chip stock ...  

On a conference call to discuss first-quarter results, Amgen Inc.'s CEO Kevin Sharer symbolically turned over the reins to Chief Operating Officer Bob Bradway, who will succeed him at the biotech giant's annual meeting on May 23. Bradway ...  

The U.S. Food & Drug Administration has rejected Amgen Inc.’s request to expand the use of its Boulder-made drug, Xgeva, and start selling it to prevent the spread of prostate cancer to bones. The decision doesn’t change the drug’s approved use in preventing bone weakening in prostate cancer patients and, under the name Prolia, to strengthen the bones of osteoporosis patients and some patients being treated for breast cancer. Xgeva is...  

The venture capital arm of Thousand Oaks-based Amgen has placed more funding into one of its portfolio companies, Sutro Biopharma, which is working on developing a scalable biochemical protein synthesis platform aimed at cancer therapeutics. Sutro said it has raised $16.5M in a second tranche of its Series C funding, which was led by Skyline Ventures, and also included Lilly Ventures, Amgen Ventures, SV Life Sciences and Alta Partners. Amgen...  

THOUSAND OAKS, Calif. (AP) — George Rathmann, who as founding CEO took Amgen Inc. from a small company with an unclear mission in a strange new field and helped turn it into the world's largest biotech drugmaker, has died at age 84. Amgen, based in Thousand Oaks, Calif., announced Rathmann's death Monday in a statement. Rathmann's son James told The New York Times he died Sunday at his home in Palo Alto, Calif. Son...  

THOUSAND OAKS, Calif. (AP) — Biotech giant Amgen Inc. says first-quarter profit rose 5 percent on higher sales of its top two drugs and two new ones, and it easily beat Wall Street forecasts. The maker of biologic drugs such as Enbrel for rheumatoid arthritis says net income was $1.18 billion, or $1.48 per share, up from $1.13 billion, or $1.20 per share, a year ago. Excluding one-time items, the Thousand Oaks...  

Pharmaceutical giants AstraZeneca PLC and Amgen Inc. just announced a deal to co-develop and co-commercialize five product candidates, all monoclonal antibodies. No surprise here: MedImmune LLC – AZ’s Gaithersburg-based biologics arm that specializes in antibody-based products — will be taking on a good deal of the work. The Maryland biotech took the lead on negotiating the transaction with Amgen and will lead the development of three of the...  

Amgen Ventures, the venture capital arm of Thousand Oaks-based Amgen, has re-upped on an investment in a biopharmaceuticals developing microRNA-based treatments for cardiovascular and muscle disease. According to miRagen Therapeutics, it has raised $20M in a Series B, which was led by Remeditex Ventures, and also included Amgen--an existing investor sin the company--along with Atlas Venture, Boulder Ventures Ltd., and Broadview Ventures...  

Osteoporosis affects more than 75 million people, with women being four times more at risk of developing the disease than men. Osteoporosis is a chronic, progressive and systemic disease, whereby the bone tissue deteriorates, losing mass and strength, which makes the bones more fragile and increases the risk of fractures. Due to estrogen deficiency, the disease accelerates during and after women's menopause as ovarian function decreases during...  

AMGEN, INC. : Amgen Sells $3 Billion In US Bond Market4-tradersBy Patrick McGee Of Amgen Inc. (AMGN) sold a $3 billion bond deal Thursday at some of the lowest yields ever for the company, thanks to ultralow Treasury rates coupled with strong demand. The Thousand Oaks, Calif.-based biopharmaceutical company sold ...and more »  

AMGEN, INC. : Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars4-tradersTHOUSAND OAKS, Calif., May 11, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that Joseph P. Miletich, MD, Ph.D., senior vice president of Research and Development at Amgen will testify at the United States (US) Food and Drug Administration ...and more »  

ONTARIO - Officials estimate between 7,000 and 10,000 spectators, including Barry Bonds, came here on Saturday to watch Stage 7 of the Amgen Tour of California begin. Related story: Gesink takes overall lead with stage win Video: Amgen Tour 2012 Special Section: Amgen  

Equity Research on Spectrum Pharmaceuticals Inc. and Amgen Inc ...MarketWatch (press release)Today they are providing members comprehensive research on the Biotechnology industry and are offering free analytical research on Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) and Amgen Inc. (NASDAQ:AMGN) . Register with us today at ...and more »  

Amgen (AMGN) Q1 2012 Earnings Call April 24, 2012 5:00 pm ET Executives Arvind Sood - Vice President of Investor Relations Kevin W. Sharer - Chairman, Chief Executive Officer, Chairman of Executive Committee and Member of Equity Award Committee Robert A. Bradway - President, Chief Operating Officer and Director Jonathan M. Peacock - Chief Financial Officer and Executive Vice President Anthony C. Hooper - Executive Vice President of Global...  

MOUNT BALDY - Rabobank rider Robert Gesink, who broke his right leg in four places after a training incident in September, took the seventh stage of the Amgen Tour of California cycling road race and the overall standings lead after winning a close battle with Jhon Atapuma on Saturday. Video: Amgen Tour 2012 Special Section: Amgen  

Arvind Sood, vice president of Investor Relations at Amgen ... Follow us on www.twitter.com/amgen. 05/01 DJ Pfizer Profit Falls 19% As Generics Hurt Lipitor Sales 05/01 DJ Pfizer Profit Falls 19% As Generics Hurt Lipitor Sales 05/01 DJ Pfizer Profit ...  

(Reuters) - U.S. health regulators rejected the application by Amgen Inc, the world's biggest biotechnology company, to expand the use of the drug Xgeva to delay the spread of tumors to the bone in patients suffering from advanced prostate cancer.  

The race is nigh. The Amgen Tour of California will soon be zipping along Alfred Harrell Highway as thousands cheer on from the starting point at Bakersfield College or other vantage points along the route. It's been two years since Bakersfield hosted, and with pent-up anticipation and massive advance coverage organizers are expecting even more of a turnout than in 2010.  

German chemical and pharmaceutical company Bayer AG (BAYN.XE) said Tuesday it has agreed with Amgen Inc. (AMGN) to develop and commercialize a new antibody for treating cancer. MAIN FACTS: -Financial details of the deal weren't disclosed. -Bayer will collaborate with Amgen at its Munich site from the research phase to the completion of initial clinical trials. -After the initial trials have been completed...  

There have been some positive first quarter results coming out of the healthcare biotechnology industry. Spectrum Pharmaceuticals Inc. recently reported first quarter earnings per share of $0.71, well above year ago earnings of $0.23 per share. Revenues ...  

Biotech giant Amgen Inc. said Tuesday that its first-quarter profit rose 5 percent on higher sales of its top two drugs and two new ones, and it easily beat Wall Street forecasts. The maker of biologic drugs such as Enbrel for rheumatoid arthritis said net income was $1.18 billion, or $1.48 per share, up from $1.13 billion, or $1.20 per share, a year ago. Excluding one-time items, the Thousand Oaks...  

Bob Bradway hasn't even taken the helm at Amgen Inc (AMGN.O), but the clock is already ticking on how the world's largest biotech will compete with rivals, including Big Pharma. Powerful value investors, who helped push up the stock 26 percent since it took a page from traditional drug companies last year with a dividend payout and stock buyback plan, are clamoring for more. But other shareholders...  

The outgoing leader of biotechnology company Amgen Inc. (AMGN) could receive payments and deferred compensation totaling more than $49 million after he retires. Kevin Sharer, 64, plans to step down as chief executive in May and as chairman at the end of 2012, after more than a decade at the helm of the Thousand Oaks, Calif., company. President and Chief Operating Officer Robert Bradway, 49, will succeed...  

Pfizer Inc. (PFE) will soon shift certain U.S. promotional responsibilities for the blockbuster anti-inflammatory drug Enbrel to its marketing partner, Amgen Inc. (AMGN), as the drug makers prepare to wind down a longstanding North American partnership  

THOUSAND OAKS, Calif. - George Rathmann, who as founding CEO took Amgen Inc. from a small company with an unclear mission in a strange new field and helped turn it into the world's largest biotech drugmaker, has died at age 84. Amgen, based in Thousand Oaks, California, announced Rathmann's death Mo  

More than 120 of the world?s best riders, including Vincenzo Nibali, David Zabriskie, Levi Leipheimer and others who?d drop you without even breathing hard, are winding their way toward Los Angeles at a pace that would kill mere mortals.  

CHICAGO (Reuters) - Monthly injections of an experimental drug from Amgen Inc slashed levels of cholesterol by up to an additional 66 percent in patients already taking statins, researchers said on Sunday, making it a potential strong rival to a similar drug being developed by Regeneron Pharmaceuticals Inc.  

Amgen Inc. will buy privately held KAI Pharmaceuticals Inc. of South San Francisco for $315 million cash. It is the first Bay Area acquisition by the world’s largest biotech company (NASDAQ: AMGN), based in Thousand Oaks, since a slew of buyouts the previous decade. KAI’s lead drug is in Phase II trials for hyperparathyroidism in patients with chronic kidney disease, but Amgen said it would provide a loan for planning of a Phase III trial...  

THOUSAND OAKS, Calif. (AP) — Amgen Inc. said Tuesday that it will pay $315 million to buy KAI Pharmaceuticals, a company that is developing a drug designed to treat a common side effect of kidney disease. The world's biggest biotech drugmaker said it will make a loan to KAI Pharmaceuticals so the company can finish planning late stage trials of KAI-4169, its most advanced drug candidate. KAI is studying the drug as a treatment for secondary...  

via marketwatch.com SAN FRANCISCO (MarketWatch) -- Amgen Inc. and AstraZeneca PLC said late Monday they were partnering to further develop and try to bring to market five biotech drugs candidates from Amgen's collection. Under the agreement, AstraZeneca will make an upfront payment of $50 million and foot 65% of the costs from 2012 to 2014. After that, the companies will split costs and share profits from the drugs after Amgen receives...  

A former researcher at Amgen Inc has found that many basic studies on cancer -- a high proportion of them from university labs -- are unreliable, with grim consequences for producing new medicines in the future. During a decade as head of global cancer research at Amgen, C. Glenn Begley identified 53 "landmark" publications -- papers in top journals, from reputable labs. Begley sought to double-check the findings before trying to build on them...  

(Reuters) - Amgen Inc and British drugmaker AstraZeneca Plc announced on Monday a major collaboration deal to jointly develop and sell five biotech drugs currently in Amgen's developmental pipeline.Related StoriesNews Corp faces proxy call for independent chairmanGunman kills 7, wounds 3 at California Christian collegeRescued round-the-world yacht racers go to U.S. hospitalJP Morgan ready final Edinburgh Airport bids - sourcesUK must sell RBS...  

Biotechnology firm Amgen is investing US$200m in an expansion programme in Ireland which will create up to 100 jobs. Some 350 construction jobs will be also created during the 19-month building period. The expansion includes the construction of an 11,700 sq-metre building extension, a new production plant, an expanded warehouse and the major refurbishment of its existing buildings. As well as this...  

THOUSAND OAKS, Calif., April 24, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) reported total revenue increased 9 percent during the first quarter of 2012 to $4,048 million versus $3,706 million in the first quarter of 2011.  Adjusted earnings per share (EPS) were $1.61 for the first...  

Irish TimesAmgen Inc. (AMGN) Set A New High Following AcquisitionRTT News(RTTNews) - Amgen Inc. (AMGN: News ) announced Wednesday that it agreed to buy 95.6 percent of shares in Turkey's Mustafa Nevzat Pharmaceuticals in an all cash transaction, valuing the company at $700 million. Amgen gapped open higher Wednesday and ...Amgen Nears Deal to Acquire Turkish CompanyWall Street JournalAmgen to pay about $700 million for Turkish drug makerLos...  

Amgen Says BiTE Antibody Blinatumomab Achieved High Rate Of Complete ResponseRTT News(RTTNews) - Amgen Inc. (AMGN: News ) announced updated results from a Phase 2 study that showed treatment with blinatumomab or AMG 103 helped achieve a high-rate of complete response or CR in 72 percent of adult patients with relapsed or refractory ...and more »  

Amgen Revives Defunct Drug as Old Therapies Seek New CureBusinessWeekBy Ryan Flinn on May 17, 2012 Amgen Inc. (AMGN) (AMGN)'s experimental drug rilotumumab, set aside by the company after it disappointed in a study, has been revived after a fresh look at data in gastric cancer found it helped a group of patients.and more »  

A former researcher at Amgen Inc has found that many basic studies on cancer—a high proportion of them from university labs—are unreliable, with grim consequences for producing new medicines in the future. During a decade as head of global cancer research at Amgen, C. Glenn Begley identified 53 "landmark" publications—papers in top journals, from reputable labs—for his team to reproduce. Begley sought to double-check the findings before trying...  

According to the drug maker, the FDA letter said the agency can't approve the supplemental biologics license application in its present form because the effect on bone metastases-free survival doesn ... Xgeva's and Prolia's combined sales in 2011 topped ...  

THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., April 10, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and KAI Pharmaceuticals today announced an agreement under which Amgen will acquire KAI, a privately held pharmaceutical company based in South San Francisco. KAI's lead product candidate, KAI-4169, is a novel agent being initially...  

BRUSSELS and THOUSAND OAKS, Calif., April 4, 2012 /PRNewswire/ -- UCB (Euronext Brussels: UCB) and Amgen (NASDAQ:AMGN) announced today the start of their sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal osteoporosis."We look forward to working with UCB on the CDP785...  

It has been one of the most lucrative monopolies of all time, yielding the biotechnology company Amgen roughly $40 billion in sales over 24 years. Now it appears to be over. The Food and Drug Administration on Tuesday approved an alternative to Amgen’s drugs for use in increasing red blood cell levels in anemic patients receiving kidney dialysis.  

World Class Field Assembled for America’s Premier Cycling Race Set for May LOS ANGELES, CA – Race organizers have named the 16 teams, including some of the world’s best international and domestic squads, to compete in the 2012 Amgen Tour of California, which will take place May 13 to 20. Comprised of United Cycling International (UCI) Pro, Pro Continental and Continental squads, the 16 world class teams chosen to participate in the 2012 race...  

By The Burrill Report: By Michael Fitzhugh The U.S. Food and Drug Administration has approved a new drug co-developed by Affymax (AFFY) and Takeda (TKPHF.PK) to treat anemia in adult dialysis patients who have chronic kidney disease.The drug, Omontys, is the first new therapy in its class to be approved for the condition since 2001 and gives Affymax access to an estimated $3 billion U.S. market for anemia drugs used for kidney dialysis...  

CHICAGO, March 28, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include...  

U.S. health regulators rejected the application by Amgen Inc, the world's biggest biotechnology company, to expand the use of the drug Xgeva to delay the spread of tumors to the bone in patients suffering from advanced prostate cancer.  

New York, May 14th (TradersHuddle.com) - Amgen Inc. (NASDAQ:AMGN) closed the trading day at $70.78, near its 50 day moving average that is set at $68.28. Amgen's price action is just above this important support level, providing a trading opportunity.  

KAI's lead product candidate, KAI-4169, is a novel agent being initially studied for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) who are on dialysis. SHPT, a component of CKD mineral and bone disorder ...  

BloombergAmgen 1Q profit up 5 pct, beats Wall Street viewsSeattle Post IntelligencerFILE - In this April 21, 2010 file photo, the exterior view of Amgen Inc. offices is shown in Fremont, Calif. Amgen Inc. says first-quarter profit rose 5 percent on higher sales of its top two drugs and two new ones, and it easily beat Wall Street ...Amgen Profit Tops Analysts' Estimate on Rising Drug SalesBusinessWeekAnalysis: New Amgen CEO must win investors...  

MT. BALDY -- Rabobank rider Robert Gesink, who broke his right leg in four places after a training incident in September, took the seventh stage of the Amgen Tour of California cycling road race and the overall standings lead after winning a ...  

ONTARIO -- Officials estimated between 7,000 to 10,000 spectators came out to Ontario, including former Major League baseball star Barry Bonds, on Saturday to watch the seventh stage begin. While the tour started at noon, city officials said they had been ...  

Catch up: It's an Amgen Tour for all ages | CYCLING: Tour of California set | Motorists to be inconvenienced by Amgen race Cycling fans and the Inland Empire will be in for a treat when the nation's most notable cycling event rides through today ...  

Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and delivers human therapeutics based on advances in cellular and molecular biology primarily in the United States, Europe, and Canada. The company markets primarily ...  

The riders included: Markel Irizar Arranburu (ESP) and Ben King (USA) of RadioShack-Nissan-Trek; Devenyns; Yannick Eijssen (BEL) of BMC Racing Team; Wilco Kelderman (NED) of Rabobank Cycling Team; Alex Howes (USA) of Garmin-Barracuda; Timothy Duggan (USA ...  

(Reuters) - Biotechnology company Amgen Inc (AMGN.O) posted a better-than-expected first quarter profit as product sales increased 8 percent, shares were bought back, and its tax rate fell. But Amgen left its full-year outlook unchanged and its ...  

The route takes riders north to Mt. Baldy Village, west on Glendora Ridge Road and East Fork Road to San Gabriel Canyon Road, south to Azusa and east in Glendora to Glendora Mountain Road. From there, the route goes back into the mountains to Mt.  

FRANKFURT -(Dow Jones)- German chemical and pharmaceutical company Bayer AG (BAYN.XE) said Tuesday it has agreed with Amgen Inc. (AMGN) to develop and commercialize a new antibody for treating cancer. -Financial details of the deal weren't disclosed.  

U.S. drug giant Amgen Inc. Amgen Inc. Latest from The Business Journals Follow this company will team with London-based AstraZeneca PLC ... and both companies will share future development costs and potential profits. For Amgen, the deal means ...  

Amgen Inc. agreed to buy closely held Mustafa Nevzat Pharmaceuticals for almost $700 million to expand in Turkey, where economic growth is boosting demand for medicines. Amgen will pay cash to get 95.6% of Mustafa Nevzat, or MN Pharmaceuticals ...  

Sagan's seventh Tour of California stage win eclipsed the record of six held by American Levi Leipheimer, a three-time race winner who is 40 seconds back alongside other race favorites including Chris Horner, Tom Danielson, Andrew Talansky and ...  

Rathmann, a farsighted entrepreneur whose small team of talented scientists created two blockbuster drugs that helped turn his upstart Thousand Oaks company, Amgen Inc., into the world's most successful biotech company, died Sunday at his Palo Alto home.  

Amgen Inc. is nearing a deal to buy Turkish generic-drug company Mustafa Nevzat Ilaç Sanayii AS for roughly $700 million, according to people familiar with the matter, in a deal that would deepen the biotech pioneer's exposure to faster-growing ...  

George Rathmann, who as founding CEO took Amgen Inc. from a small company with an unclear mission in a strange ... announced Rathmann's death Monday in a statement. Rathmann's son James told The New York Times he died Sunday at his home in Palo Alto ...  

THOUSAND OAKS, Calif. — George Rathmann, who as founding CEO took Amgen Inc. from a small company with an unclear mission in a strange new field and helped turn it into the world’s largest biotech drugmaker, has died at age 84. Amgen, based in Thousand ...  

A former researcher at Amgen Inc has found that many basic studies on cancer -- a high proportion of them from university labs -- are unreliable, with grim consequences for producing new medicines in the future.  

George B. Rathmann, a far-sighted entrepreneur whose small team of talented scientists created two blockbuster drugs that helped turn his upstart Thousand Oaks firm, Amgen Inc., into the world's most successful biotech company, died Sundayat his ...  

THOUSAND OAKS, Calif. (AP) -- Amgen Inc. is buying Turkish pharmaceutical company Mustafa Nevzat Pharmaceuticals for $700 million as part of its international expansion plans. Privately held Mustafa supplies pharmaceuticals to the hospital ...  

Among the earnings stories for Tuesday, April 24, from AP Business News: — Apple Inc., the world's most valuable company, trumped skeptics once again by reporting blowout iPhone sales. — Biotech giant Amgen Inc. says first-quarter profit ...  

Included in the breakaway were Maxime Bouet (FRA) of AG2R La Mondiale; Jeff Louder (USA) of UnitedHealthcare Pro Cycling Team; David Boily (CAN) of Team Spidertech Powered by C10; Andrew Dahlheim (USA) and Ben Jacques-Maynes (USA) of Bissell Pro Cycling ...  

LOS ANGELES (Reuters) - Bob Bradway hasn't even taken the helm at Amgen Inc , but the clock is already ticking on how the world's largest biotech will compete with rivals, including Big Pharma. Powerful value investors, who helped push up the stock 26 percent since it took a page from traditional drug companies last year with a dividend payout and stock buyback plan, are clamoring for more. But other shareholders still hope Amgen can keep...  

SANTA ROSA -- Peter Sagan overcame a flat tire with five miles left Sunday to take the first stage of ... the peloton overcame an all-day break that included Watsonville's Ben Jacques-Maynes. Sagan, Liquigas-Cannondale's top sprinter, finished ...  

Instead, Horner's main challenge likely will come from among Americans Tejay van Garderen, Tom Danielson and Andrew Talansky, and Italian star Vincenzo Nibali. The 23-year-old van Garderen (BMC Racing) has been knocking on the door of a stage ...  

Amgen Inc. (AMGN), the world’s largest biotechnology company, reported first-quarter profit that beat analysts’ estimates as sales increased of its drugs to treat infections in cancer patients. Amgen is seeking to shore up revenue as its ...  

Biotech giant Amgen Inc. says first-quarter profit rose 5 percent on higher sales of its top two drugs and two new ones, and it easily beat Wall Street forecasts. The maker of biologic drugs such as Enbrel for rheumatoid arthritis says net income was $1.18 ...  

TRENTON, N.J. (AP) -- Biotech giant Amgen Inc. said Tuesday that its first-quarter profit rose 5 percent on higher sales of its top two drugs and two new ones, and it easily beat Wall Street forecasts. The maker of biologic drugs such as Enbrel ...  

THOUSAND OAKS, Calif. — Biotech giant Amgen Inc. says first-quarter profit rose 5 percent on higher sales of its top two drugs and two new ones, and it easily beat Wall Street forecasts. The maker of biologic drugs such as Enbrel for rheumatoid arthritis ...  

SAN FRANCISCO (MarketWatch) -- Amgen Inc. said late Tuesday that its first-quarter profit rose to $1.18 billion, or $1.48 a share, from $1.13 billion, or $1.20 a share, in the year-ago period. Excluding one-time items, the biotech firm would have reported earnings of $1.61 a share in the latest quarter. Revenue rose to $4.05 billion from $3.71 billion last year. Analysts surveyed by FactSet Research estimated a quarterly profit of $1.46 a...  

While on the climb, a crash occurred, taking down several riders, including Sagan; George Hincapie (USA) of BMC Racing Team; Laurens Ten Dam (NED) of Rabobank Cycling Team; Andres Diaz Corrales (COL) of Exergy; and Josh Atkins (NZL) of the ...  

The final list of the teams includes, Team AG2R La Mondiale, Team Argos-Shimano, Team BMC, Team Orica-GreenEdge, Team Liquigas-Cannondale, Team Omega Pharma-QuickStep, Team Rabobank and Team RadioShack-Nissan. Team Garmin-Barracuda, Team Colombia ...  

Pfizer Inc. (PFE) will soon shift certain U.S. promotional responsibilities for the blockbuster anti-inflammatory drug Enbrel to its marketing partner, Amgen Inc. (AMGN), as the drug makers prepare to wind down a longstanding North American partnership.  

LOS ANGELES — George B. Rathmann, a far-sighted entrepreneur whose small team of talented scientists created two blockbuster drugs that helped turn his upstart Thousand Oaks, Calif., company, Amgen Inc., into the world’s most successful ...  

Strong reductions seen with 2-week, 4-week shots * Side effects similar to placebo in trial Monthly injections of an experimental drug from Amgen Inc slashed levels of cholesterol by up to an additional 66 percent in patients already taking statins ...  

CHICAGO, March 25 (Reuters) - Monthly injections of an experimental drug from Amgen Inc slashed levels of cholesterol by up to an additional 66 percent in patients already taking statins, researchers said on Sunday, making it a potential strong rival to a ...  

Amgen Inc. (AMGN) agreed to acquire KAI Pharmaceuticals for $315 million in cash, giving the drug maker rights to ... In connection with the deal, Amgen is providing a loan before closing to fund planning for Phase 3, or late-stage, clinical ...  

InPharmAmgen to Buy KAI Pharma for $315 MillionWall Street JournalBy PETER LOFTUS Amgen Inc. agreed to acquire closely held company KAI Pharmaceuticals for $315 million in cash, giving the drug maker rights to an experimental treatment for chronic kidney disease. The deal continues Amgen's strategy of pursuing ...Amgen To Buy KAI Pharma For $315 Million In CashFox Businessall 95 news articles »  

CHICAGO (Reuters) - Monthly injections of an experimental drug from Amgen Inc slashed levels of cholesterol by up to an additional 66 percent in patients already taking statins, researchers said on Sunday, making it a potential strong rival to a ...  

BOSTON (MarketWatch) -- Amgen Inc. said early Tuesday that it plans to buy privately-held KAI Pharmaceuticals for $315 million in cash. KAI's lead product candidate, KAI-4169, is in mid-stage development for the treatment of hyperparathyroidism in patients with kidney failure. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.  

THOUSAND OAKS, Calif.—Amgen Inc. said Tuesday that it will pay $315 million to buy KAI Pharmaceuticals, a company that is developing a drug designed to treat a common side effect of kidney disease. The world's biggest biotech drugmaker said it ...  

A former researcher at Amgen Inc has found that many basic studies on cancer -- a high proportion of them from university labs -- are unreliable, with grim consequences for producing new medicines in the future. During a decade as head of global cancer research at Amgen, C. Glenn Begley identified 53 "landmark" publications -- papers in top journals, from reputable labs -- for his team to reproduce. Begley sought to double-check the findings...  

UBS maintains a 'Neutral' on Amgen (NASDAQ: AMGN) price target raised from $69 to $71. Analyst, Matthew Roden, said, "We have updated our AMGN model following quarterly results to reflect what we believe are product trends going forward. We have increased ...  

The Complete Response Letter states that FDA cannot approve the application in its present form. The FDA determined that the effect on bone metastases-free survival (BMFS) was of insufficient magnitude to outweigh the risks (including osteonecrosis of the ...  

Amgen delivered 9% revenue growth - just enough to edge out ahead of the average Wall Street guess. Growth was helped by a double-digit increase in Neulasta (up 11%) and 7% growth in Enbrel, while Aranesp (-11%) and Epogen (-17%) offered up meaningful ...  

Amgen revenue up 9 percentPacific Coast Business TimesEnbrel, a treatment for psoriasis and arthritis, saw its sales go up 7 percent to $938 million. Adjusted earnings per share were $1.61 for the first quarter of 2012, an increase of about 20 percent compared to $1.34 last year.and more »  

The Amgen Tour of California booked its honorary 50,000th hotel room and the Santa Rosa Convention & Visitors Bureau is proud to announce that since 2006, every hotel in the city of Santa Rosa that has hosted the tour was recognized as honorable mention ...  

The drug, which will be sold under the brand name Omontys, would compete with Amgen Inc.'s Epogen, which is approved for use in the same group of patients. Amgen also makes Aranesp, another anemia treatment that is approved for a broader group of patients.  

Drug makers Amgen Inc. (AMGN) and AstraZeneca PLC (AZN, AZN.LN) said they reached a deal to jointly develop and commercialize five inflammatory disease treatments in Amgen's portfolio. The collaboration is expected to provide Amgen with ...  

Meanwhile, international product revenues increased 8% to $904 million. Revenues of Amgen's erythropoiesis-stimulating agent ( ESA) Aranesp fell 11% to $518 million (US: $202 million, down 19%; ex-US: $316 million, down 4%). US sales were down ...  

The candidates to be developed under this agreement include brodalumab (psoriasis - phase III to commence, psoriatic arthritis and asthma - phase II), AMG 139 ... D spend and share the risks associated with product development. AstraZeneca should be ...  

The government of Recep Tayyip Erdogan, which has Islamist roots but prefers to label itself as conservative, has carried out large-scale health reforms, which have markedly increased many people’s access to medical services. Some 98 per cent ...  

Consensus estimates for Abbott's EPS forecast that it will grow by 7.5% to $ ... Towards that end, management's hiring of Jeremy Levin as CEO, who comes with a history of overseeing takeovers at Bristol Myers (BMY), is a solid step in the right direction.  

Earnings, however, increased 3.5% from the year-ago period. A lower tax rate, lower share count and higher revenues contributed to the year-over-year increase in earnings. Total revenue increased 3% to $3,973 million in the fourth quarter of 2011.  

Our buy stance remains unchanged but our conviction has increased. The company has been transformed under chief executive Angela Ahrendts’ strategy, but we feel there is much more to come and forecast around 360 basis points of retail/wholesale operating ...  

Now that we've cleaned up the roadway, the East Bay can roll out the red carpet for America's premier bicycle race. Organizers of the Amgen Tour of California announced in February that the eight-day, 750-mile event will once again include ...  

George Rathmann, who helped build Amgen Inc from a start-up into the world's biggest biotechnology company as its founding CEO, died on Sunday, the firm said in a statement. He was 84.  

Final Glance: Biotechnology companiesCBS NewsNEW YORK — Shares of some top biotechnology companies were down at the close of trading: Amgen Inc. fell $1.39 or 2.0 percent, to $69.15. Biogen Idec fell $1.30 or 1.0 percent, to $131.58. Celgene Corp. fell $.97 or 1.4 percent, to $68.10.and more »  

Notable ETF Inflow Detected - TQQQ, ALXN, ALTR, AMGNForbes(NASD: ALTR) is up about 0.1%, and Amgen Inc (NASD: AMGN) is lower by about 1.7%. For a complete list of holdings, visit the TQQQ Holdings page » Looking at the chart above, TQQQ's low point in its 52 week range is $25.63 per share, with $62.49 as the ...and more »